Payment & Shipping Terms:
|Name:||Venetoclax||Synonym:||ABT - 199|
668270 12 0,
1377049 84 7
Venetoclax , ABT - 199 , CAS No . : 1257044-40-8 GMP condition
Name : Venetoclax
CAS No . : 1257044-40-8
Chemical Name : 4 - ( 4 - ( ( 2 - ( 4 - chlorophenyl ) - 4 , 4 - dimethylcyclohex - 1 - en - 1 - yl ) methyl ) piperazin - 1 -yl ) - N - ( ( 3 - nitro - 4 - ( ( tetrahydro - 2H - pyran - 4 - ylmethyl ) amino ) phenyl ) sulfonyl ) - 2 - ( 1H - pyrrolo ( 2 , 3-b ) pyridin - 5 - yloxy ) benzamide
Molecular Formula : C45H50ClN7O7S
Molecular Weight : 868.44
Description : Venetoclax is the active pharmaceutical ingredient of brand drug Venclexta or Venclyxto. It is normally combined with rituximab to treat chronic lymphocytic leukemia ( CLL ) or small lymphocytic leukemia ( SLL ) in those who have failed in first line treatment. It was approved in 2016 by US FDA and EMA. The drug company AbbVie Inc manufactures the drug but AbbVie and Genetech USA ( a memeber of Roche Group ) both mareket it in the US. Only AbbVie has right to do so outside US.
The forecast 2020 sales of this drug by Reuters 2016 Drugs to Watch is USD1.48 billion.
The drug is protected by patent owned by Abbvie. We only sell it to non patent protected countries or areas. The sale to patent protection countries and areas is only for R & D purpose. The buyers should take all responsiblity of patent status in his countries or areas.
Competitive Advantage: Produced under cGMP conditions, support customers’ registrations